摘要
目的探讨人免疫球蛋白辅助治疗小儿重症肺炎的临床效果。方法选取本院2013年6月~2014年11月收治的80例小儿重症肺炎患者作为研究对象,随机分成观察组和对照组,各40例。对照组采用常规治疗,包括抗生素治疗、抗病毒治疗、吸氧以及纠正患者心力衰竭等。观察组在对照组的基础上给予人免疫球蛋白辅助治疗,比较两组的治疗效果。结果观察组的治疗总有效率显著高于对照组,差异有统计学意义（P〈0.05）。观察组患者的退热时间、咳嗽消失时间、啰音消失时间、X线胸片检查炎症吸收时间以及总住院时间显著短于对照组,差异有统计学意义（P〈0.05）。观察组治疗后的Ig G水平显著低于对照组,差异有统计学意义（P〈0.05）。结论人免疫球蛋白辅助治疗小儿重症肺炎效果显著,能够有效缩短退热时间、咳嗽消失时间、啰音消失时间、X线胸片检查炎症吸收时间以及总住院时间,降低患者血清中的Ig G水平,值得临床推广应用。
Objective To explore the clinical efficacy of human immunoglobulin as an adjuvant therapy in the treat- ment of pediatric severe peumonia. Methods 80 children with severe pneumonia from June 2013 to November 2014 in our hospital were selected and randomly divided into the control group and the observation group,40 cases in each group.The control group was treated with conventional treatment including antibiotics,anti-virus,oxygen inhalation and heart failure correcting,the observation group was given human immunoglobulin as an adjuvant therapy on the basis of control group.The therapeutic effect in two groups was compared. Results The total effective rate in the observation group was higher than that in the control group,with significant difference （P〈0.05）.The time of fever subsidence,cough disappeared time,rales disappear time,X-ray examination inflammation absorption time and the total hospitalization time in the observation group was shorter than that in the control group,with significant difference （P〈0.05）.The level of serum IgG after treatment in the observation group was lower than that in the control group,with significant difference （P〈0.05）. Conclusion The effect of human immunoglobulin as an adjuvant therapy in the treatment of pediatric severe pneumonia is significant,which can effectively shorten the time of fever subsidence,cough disappeared time,rales disap- pear time,X-ray examination inflammation absorption time and the total hospitalization time,reduce serum IgG level,it is worthy of clinical promotion and application.
出处
《中国当代医药》
2015年第26期70-72,75,共4页
China Modern Medicine
关键词
人免疫球蛋白
小儿重症肺炎
临床疗效
Human immunoglobulin
Pediatric severe pneumonia
Clinical efficacy
